Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, Jonathan Chipman, Victor Sacristan Santos, Stephanie Erickson, Divya Dharmaraj, Ajjai Shivaram Alva, Ulka N. Vaishampayan, John Esther, Andrew W. Hahn, Benjamin Louis Maughan, Emmanuel S. Antonarakis, Neeraj Agarwal

Research output: Contribution to journalArticlepeer-review

Abstract

Presence of tumor mutation in speckle-type pox virus and zinc finger protein (SPOP) gene was associated with improved survival outcomes in men with de novo metastatic castration-sensitive prostate cancer receiving standard androgen deprivation therapy.

Original languageEnglish (US)
Pages (from-to)652-656
Number of pages5
JournalEuropean Urology
Volume78
Issue number5
DOIs
StatePublished - Nov 2020
Externally publishedYes

Bibliographical note

Funding Information:
Funding/Support and role of the sponsor: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014 to Huntsman Cancer Institute at the University of Utah, P30CA006973 to Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, and 3P30CA042014-25S2 to N. Agarwal. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Publisher Copyright:
© 2020 European Association of Urology

Keywords

  • Androgen deprivation therapy
  • Metastatic hormone-sensitive prostate cancer
  • Overall survival
  • Progression-free survival
  • SPOP

PubMed: MeSH publication types

  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer'. Together they form a unique fingerprint.

Cite this